Goldman Sachs Starts Centessa Pharmaceuticals (CNTA) at Buy
Get Alerts CNTA Hot Sheet
Rating Summary:
5 Buy, 2 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $42.00.
The analyst comments "CNTA is an umbrella company reimagining the R&D model and leveraging asset centricity at scale (ten subsidiaries, each led by a team of subject matter experts, are under the management of a centralized team with oversight capabilities). Four clinical stage programs are underway: Ph3 lixivaptan in autosomal dominant polycystic kidney disease (ADPKD; $2.1bn peak global sales), Ph2 serpinPC in hemophilia A and B ($1.4bn peak global sales), Ph1 ZF874 in alpha-1 antitrypsin deficiency (A1AT; $5.5bn peak global sales), and Ph2-ready imgatuzumab in cutaneous small cell carcinoma (CSCC; $476mn peak global sales), all of which will have value driving catalysts in 2021. Data from the first three programs will provide clarity on differentiation of the clinical profile, and we note the other 12 programs from the pipeline offer optionality."
For an analyst ratings summary and ratings history on Centessa Pharmaceuticals click here. For more ratings news on Centessa Pharmaceuticals click here.
Shares of Centessa Pharmaceuticals closed at $24.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Centessa Pharmaceuticals (CNTA) Announces Pricing of $100 Million Public Offering of American Depositary Shares
- AGNC Investment Corp (AGNC) PT Lowered to $10.25 at Jones Trading
- Boston Beer Company (SAM) PT Lowered to $325 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!